SCHEMBL4295213

SCHEMBL4295213

Cc1cccc2scc(C(=O)O)c12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.47
ALDH1A1 P00352 2/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 2/20 0.47
MYC P01106 1/20 0.43
CTSG P08311 3/20 0.42
CMA1 P23946 3/20 0.42
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.39
AKR1B10 O60218 1/20 0.39
TRPA1 O75762 1/20 0.39
ABCB11 O95342 1/20 0.39
DHFR P00374 1/20 0.39
LMNA P02545 1/20 0.39
MPO P05164 1/20 0.39
CYP1A2 P05177 1/20 0.39
CHRM1 P11229 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6130704 0.80 KDM4E (0.45) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL4298267 0.79 TSHR (0.50) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL6130745 0.79 TSHR (0.44) KDM4EALDH1A1HSD17B10KMT2ACYP1A2
SCHEMBL14886651 0.79 ALB (0.47) KDM4EALDH1A1HPGDHSD17B10KMT2A
SCHEMBL5351904 0.75 TAS2R14 (0.41) ALDH1A1HPGDKMT2AMEN1LMNA
SCHEMBL8404359 0.74 CTSG (0.37) ALDH1A1CTSGCMA1TRPA1CYP1A2
SCHEMBL5178307 0.73 TRPA1 (0.41) KDM4EALDH1A1HPGDHSD17B10CTSG
SCHEMBL31721926 0.72 ALB (0.41) KDM4EALDH1A1HSD17B10MYCKMT2A
SCHEMBL6327715 0.71 ALDH1A1 (0.41) ALDH1A1CTSGCMA1CYP1A2TSHR
SCHEMBL13888151 0.70 CTSG (0.47) ALDH1A1CTSGCMA1CYP1A2RXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264663-A1 3-HYDROXYMETHYLBENZO[b]THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJEN PHARMA LIMITED (JP) 2009-10-22 US disclosed
US-20090264663-A1 3-HYDROXYMETHYLBENZO[b]THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJEN PHARMA LIMITED (JP) 2009-10-22 US disclosed
US-20090264663-A1 3-HYDROXYMETHYLBENZO[b]THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION TEIJEN PHARMA LIMITED (JP) 2009-10-22 US disclosed
EP-1947096-A1 3-HYDROXYMETHYLBENZO[b]THIOPHENE DERIVATIVE AND METHOD FOR PRODUCING SAME Teijin Pharma Limited (JP) 2008-07-23 EP disclosed
EP-1947096-A1 3-HYDROXYMETHYLBENZO[b]THIOPHENE DERIVATIVE AND METHOD FOR PRODUCING SAME Teijin Pharma Limited (JP) 2008-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264663-A1 3-HYDROXYMETHYLBENZO[b]THIOPHENE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION CMA1, TPSB2, TPSAB1 KDM4E 205/4885ALDH1A1 1138/4885HPGD 709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.